Steroid drugs used for HRT can combat E. coli and MRSA

2024-03-13

合格传染病产品

Researchers have combined computational and microbiology laboratory approaches to identify existing drugs that can be repurposed to combat antibiotic-resistant bacterial infections. This research has revealed that a class of steroid drugs currently used in hormone replacement therapy (HRT) can also stop the growth of antibiotic-resistant E. coli and effectively kill MRSA. The emergence of drug-resistant bacteria is a global threat to human health, and the development of new antibiotics from scratch is an extremely expensive and time-consuming process. To address this urgent issue, researchers from the University of Kent's School of Biosciences have combined computational and microbiology laboratory approaches to identify existing drugs that can be repurposed to combat antibiotic-resistant bacterial infections. This research, which has been published in the Journal of Infectious Diseases, revealed that a class of steroid drugs currently used in hormone replacement therapy (HRT) can also stop the growth of antibiotic-resistant E. coli and effectively kill MRSA. These drugs are particularly good at binding to a protein complex, cytochrome bd, which is important for the growth and survival of a range of disease-causing bacterial species. It is expected that steroids may provide an alternative to conventional antibiotics that are becoming increasingly ineffective. Dr Mark Shepherd, Reader in Microbial Biochemistry at Kent and the corresponding author on the paper, said: 'These exciting developments will help to advance research into new antimicrobials, and we are enthusiastic to use our powerful experimental approach to discover drugs that can target other bacterial proteins and combat a wide range of antibiotic-resistant infections.' The article 'Steroid Drugs Inhibit Bacterial Respiratory Oxidases and Are Lethal Toward Methicillin-Resistant Staphylococcus aureus' is published in the Journal of Infectious Diseases (University of Kent: Samantha A. Henry, Calum M. Webster, Mark N. Wass, Gary K. Robinson and Mark Shepherd).

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构